The *B-cell translocation gene 2* (*BTG2*) belongs to the APRO (*a*nti*pro*liferative) gene family and is generally considered to exert antioncogenic activities ([@bib28]; [@bib8]; [@bib24]). Specifically, *BTG2* has been shown to inhibit cell proliferation and to induce either G1 or G2 cell cycle arrest, depending on the cellular context ([@bib33]; [@bib25]; [@bib17]; [@bib19]). In addition, *BTG2* can counteract *ras*-induced cellular transformation ([@bib1]), induce cellular differentiation ([@bib9]), and enhance the activity of pro-apoptotic stimuli ([@bib26]). Consistent with a putative tumour-suppressor function, *BTG2* expression is downregulated during tumour progression in breast cancers ([@bib22]), gliomas ([@bib3]), and prostate cancers ([@bib11]). Moreover, low or absent *BTG2* expression levels in tumours have been shown to correlate with a less favourable clinical prognosis for breast and prostate cancer patients ([@bib37]; [@bib30]; [@bib21]).

Bladder cancer is a major human cancer with estimated 357 000 new cases diagnosed each year. Approximately 145 000 patients per year will die from the disease ([@bib31]). Bladder cancer originates in ∼90% from the urothelial (transitional) epithelium of the bladder mucosa ([@bib38]). Additional histological forms of bladder cancers include squamous cell carcinoma (SCC) that is relatively rare in Western countries, where it constitutes \<5% of all bladder cancers ([@bib32]).

Numerous genetic and epigenetic alterations are found in urothelial bladder cancers ([@bib38]; [@bib29]). Over 50% of cases exhibit defects in p53-linked tumour-suppressor pathways ([@bib38]). Inactivating somatic alterations of the retinoblastoma tumour-suppressor gene, *RB1*, are also prevalent in urothelial carcinomas and have been associated with more invasive tumour variants ([@bib2]). Furthermore, a large proportion of urothelial cancers exhibit aberrant activation of mitogenic signalling pathways linked to the Ras oncoprotein, for example, via somatic *ras* gene mutations that occur in 30--40% of all urothelial bladder cancers ([@bib38]) or via missense mutations of the *FGFR3* receptor tyrosine kinase gene ([@bib4]) that acts as an upstream regulator of HRas ([@bib38]).

To the best of our knowledge, the status of the *BTG2* gene in bladder cancer has not been examined thus far. To address this issue, we (1) analysed *BTG2* expression in bladder cancer cells *in vitro*, (2) tested phenotypic alterations of bladder cancer cells upon silencing of endogenous *BTG2* expression by RNA interference (RNAi), (3) investigated BTG2 protein expression in bladder cancer cystectomy specimens by immunohistochemistry, and (4) examined a possible correlation between BTG2 expression levels in the tumours and the clinical prognosis of bladder cancer patients.

Materials and methods
=====================

Cells and transfections
-----------------------

All cell lines investigated in this study were authenticated by short tandem repeat profiling or multiplex cell authentication ([@bib5]). All analysed bladder cancer cell lines were derived from urothelial cancers, with the exception of SCaBER cells that were derived from a SCC. Cells were maintained in either RPMI or DMEM (pH 7.2) medium, supplemented with 10% FCS, 50 units ml^−1^ penicillin, and 50 mg ml^−1^ streptomycin sulphate. Cells were transfected with synthetic siRNAs (Silencer Select, Life Technologies, Darmstadt, Germany; final concentration of 30 nℳ) with Dharmafect (Dharmacon, Thermo Fisher Scientific, Lafayette, CO, USA) or with Lipofectamine RNAiMax (Life Technologies). The siRNAs employed in the study targeted the following sequences: siEGFP (5′-GGAGCGCACCAUCUUCUUC-3′), sicontr-1 (5′-CAGUCGCGUUUGCGACUGG-3′) ([@bib20]), siNeg (5′-UACGACCGGUCUAUCGUAG-3′) ([@bib20]), siBTG2-3 (5′-GCUCCAUCUGCGUCUUGUA-3′), siBTG2-5 (5′-GAGGCACUCACAGAGCACU-3′), and siBTG2-9 (5′-UGAGCGAGCAGAGGCUUAA-3′). The *BTG2*-targeting siRNAs bind to non-overlapping domains within the *BTG2* mRNA and were applied either alone or in equimolar combination.

All functional analyses (see below) were independently performed at least three times, with consistent results.

Migration assays
----------------

Wound healing assays were performed using Culture-Inserts (ibidi, Martinsried, Germany), following the manufacturer\'s instructions. Briefly, cells were plated 24 h after transfection onto 24-well plates that contained inserts to generate defined 'scratch areas\'. Inserts were removed after the cells had grown confluent. Cells that had migrated into the scratch areas were visualised after 8--10 h by light microscopy.

Boyden chamber assays were performed using ThinCert- cell culture inserts with a 0.8 *μ*m pore size membrane (Greiner Bio-One, Frickenhausen, Germany), following the manufacturer\'s protocol. Briefly, cells were added onto the upper membrane side in the upper chamber 48 h after transfection. Cells that had moved to the lower membrane side were fixed after 24 h and stained with crystal violet.

BrdU assays
-----------

Cell proliferation was quantified by measuring BrdU incorporation into the DNA, using the Cell Proliferation ELISA kit (Roche Diagnostics, Mannheim, Germany). Cells were labelled with BrdU for 16 h, harvested 72 h after transfection, and further processed following the manufacturer\'s instructions.

Cell cycle analyses
-------------------

Cells were trypsinised 72 h after transfection, washed in ice-cold phosphate-buffered saline (PBS), and fixed in 80% cold ethanol overnight at −20 °C. Subsequently, cells were pelleted, resuspended in PBS containing 1 mg ml^−1^ RNAse A (Roche Diagnostics) and 25 mg ml^−1^ propidium iodide (Sigma-Aldrich, München, Germany), and incubated for 30 min at RT. Cell cycle analyses were performed using FACSCalibur (BD Biosciences, Heidelberg, Germany) with CellQuest Pro software. Quantitation of the percentage of cells in individual cell cycle phases was performed using FlowJo software (Tree Star, Ashland, OR, USA), applying the Dean-Jett-Fox model ([@bib12]).

RNA extraction, quantitative real-time reverse transcription--PCR (qRT--PCR), and immunoblot analyses
-----------------------------------------------------------------------------------------------------

The RNA was purified using PureLink RNA Mini Kit (Life Technologies). The RNA concentrations were measured with NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE, USA), at 260 nm. Reverse transcription of 1 *μ*g RNA was performed using the oligo-dT primer and ProtoScript M-MuLV Taq RT--PCR Kit (New England Biolabs, Frankfurt, Germany). Expression levels were determined by real-time PCR with a 7300 Real-Time PCR System detector (Life Technologies), using the SYBR green PCR Master Mix (Life Technologies), supplemented to 500 nℳ of each forward and reverse primer. The BTG2 (NM_006763.2) expression was determined using forward primer 5′-CTCACCTGCAAGAACCAAGTG-3′ and reverse primer 5′- AGTTCCCCAGGTTGAGGTATGT-3′. The GAPDH primer sequences and cycling conditions have been previously described ([@bib13]). The sizes of the PCR products were initially verified by agarose gel electrophoresis and subsequently checked by melting point analysis after each reaction. Relative quantification was performed using the comparative Ct (2^−ΔΔCt^) method ([@bib27]). Data are presented as the fold difference in gene expression normalised to GAPDH and relative to a calibrator sample. Statistical significance of differences in measured variables between controls and treated groups was determined by paired *t*-test using the Sigma Plot software (Systat Software Inc., San Jose, CA, USA). Differences were considered significant at *P*\<0.05.

For immunoblot analyses, total protein extracts were prepared 72 h after transfection, as described previously ([@bib20]). Briefly, 30 *μ*g of protein extract was separated by 12.5% SDS--PAGE, transferred to an Immobilon-P membrane (Millipore, Bedford, MA, USA), and analysed by enhanced chemiluminescence (GE Healthcare, Buckinghamshire, UK) using a rabbit polyclonal anti-BTG2 antibody (GenWay Biotech, San Diego, CA, USA) or an anti-*α*-tubulin antibody (CP06, Calbiochem, Darmstadt, Germany).

Patients
--------

Clinical data of patients (*n*=273) who underwent radical cystectomy between 1998 and 2009 for muscle-invasive and refractory nonmuscle-invasive urinary bladder cancer (histopathological subtypes: urothelial carcinoma, SCC, and others) at three centres (Departments of Urology, Universities of Heidelberg and Bonn, Germany, and University of Mansoura, Egypt) were entered into a tumour database. Tumour stage was classified according to the tumour node metastasis staging system of 2002 ([@bib16]) Patients were prospectively evaluated every 3 months for the first 2 years after surgery, every 6 months for the next 3 years, and yearly thereafter (chest X-ray or thoracic CT scan; abdominal/pelvic sonography or CT scan or MRI; X-ray intravenous urography or CT urography or MRI urography; urine cytology; serum chemistry). Chemotherapy regimens consisted of methotrexate, vinblastine, epirubicin, cisplatin, and gemcitabine. Of the 273 patients, 5 (1.8%) received neoadjuvant chemotherapy, 43 (15.8%) patients underwent adjuvant chemotherapy, and 2 (0.7%) patients underwent adjuvant radiation therapy for positive lymph node status and/or extravesical extension. The work was covered by a votum of the ethical committee of the University of Heidelberg No. 206/2005. Informed and/or written consent was obtained from each patient. Clinical and pathological features of patients scored for BTG2 expression (*n*=183; urothelial carcinoma of the bladder *n*=127, SCC of the bladder *n*=46, other histopathological subtypes *n*=10) after exclusion of insufficient tumour tissue or fixation artefacts are summarised in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

Tissue microarrays
------------------

A tissue microarray (TMA) containing 273 primary tumour tissue samples was created by the tissue bank of the National Center for Tumor Diseases (NCT) Heidelberg. Representative tissue blocks were selected as donor blocks for the TMA. Sections were cut from each donor block and stained with haematoxylin and eosin. Then, a morphologically representative region was chosen from each of the bladder cancers. At least one cylindrical core tissue specimen per tumour block (diameter, 0.6 mm) was punched from these regions and arrayed into the recipient paraffin block using a semiautomatic system (Beecher Instruments, Silver Spring, MD, USA).

Immunohistochemistry
--------------------

Tissue microarray slides were dewaxed and rehydrated using xylene and a series of graded alcohols, followed by heat-induced antigen retrieval using a target retrieval solution (S2031, DakoCytomation, Glostrup, Denmark) in a pressure cooker for 10 min. Immunohistochemical staining was performed on an automated staining system (Techmate 500, DakoCytomation) with a 1 : 200 dilution of an anti-BTG2 antibody (GenWay Biotech) ([@bib30]) for 30 min. An avidin-biotin-complex peroxidase technique using aminoethylcarbazole for visualisation and haematoxylin for counterstaining was applied. We used the following materials: ChemMate Detection Kit (K5003, DakoCytomation), ChemMate Buffer Kit (K5006, DakoCytomation), and, for reduction of nonspecific avidin/biotin-related staining, the Avidin/Biotin Blocking Kit (SP-2001, Vector Laboratories, Burlingame, CA, USA). Sections were thoroughly washed, glass covered, and analysed by light microscopy (Olympus Vanox-T, Hamburg, Germany) using a magnification of up to × 400. As negative control for the immunohistochemical staining procedure, the primary antibody was omitted, with all other experimental conditions kept constant.

For immunohistochemical assessment of BTG2 expression, the product of the scores of staining frequency and intensity of immunoreactive tumour cells was calculated on the following scoring system: the frequency ranged from 0% to 100% of BTG2-positive tumour cells, and the intensity comprised 0=no to 3=high. The final immunohistochemical score (ranging from 0 to 300) is obtained by multiplication of the intensity score and the frequency score. A cutoff between low, moderate, and high expression was set as follows: low BTG2 expression, ⩽20; moderate BTG2 expression, \>20--160; and high BTG2 expression, \>160--300. These immunohistochemical scores were determined using the sample quartiles (Q1=lower quartile, Q2=median, and Q3=upper quartile) as cut-points for categorisation of the continuous variable BTG2 expression. The arrays were independently scored by two researchers (NW and GH) blinded for patient outcomes. For the few instances of discrepant scoring, a consensus score was determined.

Study design
------------

A retrospective study design was chosen. The cancer-specific survival of patients was calculated from the date of bladder surgery. The survival end point was the date of last follow-up or date of death because of cancer. Kaplan--Meier estimates were used to describe survival rates including pointwise asymptotic 95% confidence intervals using Greenwood\'s formula for standard error. Patients with proven tumour-independent death were censored. The following clinical and pathological features were studied for their prognostic relevance on long-term survival of urinary bladder cancer patients: age (\<65 years *vs* ⩾65 years), sex (male *vs* female), tumour stage (T2, T3, T4 *vs* T1), lymph node involvement (negative *vs* positive), metastases (M0 *vs* M1), grading (grade 2, 3/4 *vs* 1), histopathological subtype (urothelial carcinoma *vs* SCC *vs* other types), concomitant carcinoma *in situ* (negative *vs* positive), lymphovascular invasion (negative *vs* positive), and cytoplasmic/membranous BTG2 expression (moderate, high *vs* low).

Statistical analysis
--------------------

Association between important prognostic factors and BTG2 levels was evaluated by Fisher\'s exact test. For the evaluation of prognostic factors, the study population was left as a whole cohort of patients (all histologies) or divided into subgroups of urothelial carcinoma and SCC of the bladder. No data-driven combination of adjacent categories related to BTG2 expression was carried out to retain the confirmatory nature of the evaluation of BTG2. Univariate and multivariate analyses of prognostic factors were carried out within the Cox proportional hazards model using complete case analysis. For each prognostic factor the hazard ratio in the univariate analysis and the adjusted hazard ratio in the multivariate analysis are given, including the 95% confidence interval. A *P*-value of \<0.05 was considered significant. For further description of the predictive value of BTG2, the concordance probability ([@bib15]) of the Cox model including BTG2 were calculated and compared with the model excluding BTG2 but retaining all other variables. Additionally, a multivariate analysis with the BTG2 expression as continuous predictor and the clinicopathological characteristics as categorical predictors was performed, using the multivariate fractional polynomial (MFP) approach ([@bib34]). With this method, it was possible to keep the BTG2 predictor as a continuous variable. The statistical analysis system SAS, Version 9.3 for Windows (SAS Institute Inc., Cary, NC, USA) was used for these analyses. For the calculation of the concordance probability and the associated standard errors, the SAS Code offered by [@bib15]) was used.

Results
=======

BTG2 expression in bladder cancer cell lines
--------------------------------------------

In order to analyse the expression of the *BTG2* gene in bladder cancer cells *in vitro*, we investigated a panel of five tumour-derived bladder cancer cell lines by qRT--PCR. All tested cell lines expressed detectable levels of *BTG2* mRNA, showing differences in relative amounts ranging up to approximately three levels of magnitude ([Figure 1A](#fig1){ref-type="fig"}). The expression of *BTG2* has been reported to be enhanced with increasing cell density in renal cell carcinoma cells ([@bib35]). In line with this finding, SCaBER bladder cancer cells also exhibited a significant induction of *BTG2* mRNA concentrations (3.4-fold) at confluency when compared with *BTG2* expression levels under semiconfluent conditions ([Figure 1A](#fig1){ref-type="fig"}). In contrast, however, RT4, RT112, T24, and 5637 cells did not show significant alterations of *BTG2* mRNA amounts when compared at semiconfluent or confluent conditions ([Figure 1A](#fig1){ref-type="fig"}).

Next, we tested whether *BTG2* expression in bladder cancer cells can be modulated by agents that have been reported to affect *BTG2* levels in other cell types. The *BTG2* gene is transcriptionally activated by p53 that can mediate *BTG2* induction by genotoxic agents, like doxorubicin ([@bib33]; [@bib10]; [@bib26]) or ionising radiation ([@bib33]). As previously reported ([@bib33]), doxorubicin treatment led to an increase of *BTG2* mRNA levels in MCF-7 breast cancer cells that served as a positive control for our experiments ([Figure 1B](#fig1){ref-type="fig"}). A comparably high induction of *BTG2* expression was observed for T24 bladder cancer cells. In contrast, however, *BTG2* mRNA levels were only marginally increased, if at all, in RT4, RT112, SCaBER, and 5637 bladder cancer cells ([Figure 1B](#fig1){ref-type="fig"}).

In addition, *BTG2* mRNA levels can be enhanced in MCF-7 cells by retinoic acid (r.a.) treatment, suggesting that r.a. may act antiproliferative in these cells via *BTG2* stimulation ([@bib7]). In accordance with this study, we also observed a clear upregulation of *BTG2* mRNA levels in MCF-7 cells following r.a. treatment ([Figure 1C](#fig1){ref-type="fig"}). In contrast, however, none of the tested bladder cancer cell lines (RT4, RT112, SCaBER, and T24) exhibited a more than marginal increase in *BTG2* expression, if at all, indicating that r.a.-mediated *BTG2* induction is largely abolished in these cells ([Figure 1C](#fig1){ref-type="fig"}).

For RNAi analyses, we generated synthetic siRNAs that target different regions of the *BTG2* transcript. [Figure 1D](#fig1){ref-type="fig"} shows that these siRNAs substantially reduced *BTG2* mRNA concentrations, indicating that *BTG2* is amenable to RNAi-mediated suppression in bladder cancer cells. The inhibitory effects of RNAi was also observed at the protein level, as shown for RT112 cells ([Figure 1E](#fig1){ref-type="fig"}). For subsequent functional investigations, we concentrated on RT112, T24, SCaBER, and 5637 bladder cancer cells as these cells could be efficiently transfected and exhibited a substantial downregulation of endogenous *BTG2* expression by RNAi ([Figure 1D](#fig1){ref-type="fig"}).

BTG2 silencing blocks the migration capacity of bladder cancer cells
--------------------------------------------------------------------

In order to assess the phenotypic effects of *BTG2* suppression in bladder cancer cells, we tested their proliferative activity by analysing BrdU incorporation into the cellular DNA. Under experimental conditions where a substantial reduction of endogenous *BTG2* expression is achieved by RNAi ([Figure 1D](#fig1){ref-type="fig"}), we did not observe increased cellular proliferation for any of the tested bladder cancer cell lines ([Figure 2A](#fig2){ref-type="fig"}). Rather, *BTG2* inhibition led to a slight decrease in cellular proliferation. Thus, our data indicate that suppression of endogenous *BTG2* expression does not enhance cell proliferation of bladder cancer cell lines. In line with this interpretation, we also did not observe appreciable alterations in cell cycle distributions of bladder cancer cells upon inhibition of *BTG2* expression ([Figure 2B](#fig2){ref-type="fig"}).

The suppression of *BTG2* by RNAi has been linked to increased cell migration in breast cancer cells ([@bib36]). In order to investigate whether *BTG2* may contribute to the regulation of this process in bladder cancer cells, *BTG2* expression was repressed by RNAi in RT112, T24, SCaBER, and 5637 cells. Subsequently, the migration potential of the cells was compared with control-transfected cells in 'wound healing (scratch)\' assays ([@bib23]). Contrary to the findings reported for breast cancer cells, we observed a substantially decreased migration rate for all four investigated bladder cancer cell lines upon suppression of endogenous *BTG2* expression. A representative assay is shown for 5637 cells in [Figure 3A](#fig3){ref-type="fig"}, and a compilation of the results for all four tested bladder cancer cell lines is presented in [Figure 3B](#fig3){ref-type="fig"}.

To investigate this issue by an independent experimental method, we performed 'Boyden chamber\'-based motility assays ('filter membrane migration assays\'). In contrast to the monolayer wound healing assay, the Boyden chamber assay is a two-compartment assay that requires cells to release intercellular contacts in order to migrate through a porous membrane ([@bib6]). Again, all four tested bladder cancer cell lines exhibited a substantially decreased migratory activity upon suppression of *BTG2* expression ([Figure 4](#fig4){ref-type="fig"}).

Taken together, these results show that silencing of endogenous *BTG2* expression markedly reduces the motility of bladder cancer cells and thus indicate that *BTG2* substantially contributes to their migratory activity.

Differential BTG2 expression in distinct histologies of bladder cancer
----------------------------------------------------------------------

In order to investigate BTG2 expression in urinary bladder cancer *in vivo*, a multi-institutional TMA was constructed. Expression of BTG2 was analysed by immunohistochemistry. Altogether, 183 cases were scored for BTG2 expression. Cases with insufficient tumour tissue or fixation artefacts (*n*=90) were excluded from further analyses.

Typical examples of BTG2 protein expression in urinary bladder cancers are depicted in [Figure 5](#fig5){ref-type="fig"}. In the cytoplasm and/or at the cell membrane of bladder cancer cells ([Figure 5A and B](#fig5){ref-type="fig"}), BTG2 was detected, as has been previously reported for the BTG2 expression pattern in breast cancer cells ([@bib30]). Notably, the amounts of BTG2 expression differed between the distinct bladder cancer histologies. In urothelial carcinomas, 75 samples (59.0%) exhibited high (immunohistochemical score: \>160--300) BTG2 levels ([Figure 5A](#fig5){ref-type="fig"}), 41 cases (32.3%) moderate (\>20--160) BTG2 levels ([Figure 5B](#fig5){ref-type="fig"}), and only 11 cases (8.7%) low (⩽20) BTG2 levels ([Figure 5C](#fig5){ref-type="fig"}). In contrast, the large majority of SCCs (37 out of 46 samples=80.4%) displayed only low (⩽20) BTG2 levels, with most samples exhibiting undetectable BTG2 expression ([Figure 5D](#fig5){ref-type="fig"}). Only six SCC samples displayed moderate (\>20--160) BTG2 levels and three SCC samples exhibited high (\>160--300) BTG2 levels.

BTG2 expression correlates strongly with cancer-specific survival in urinary bladder cancer
-------------------------------------------------------------------------------------------

Next, the survival of patients with urinary bladder cancer was calculated from the time of bladder surgery. Median follow-up of patients still alive (*n*=95) was 6.7 years (range 0.1--11.7 years). Until July 2010, 63 patients (34.4%) had died of their disease. The cancer-specific survival rate at 1 year and at 5 years after surgery for the whole cohort of patients was 82.6% (95 CI 76.2--87.4%) and 64.9% (95 CI 57.3--71.5%), respectively. The clinical and pathological features of patients are summarised in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

Patients with one of the following criteria (age⩾65 years, advanced tumour stages (T3 and T4), high grading (grade 3/4), no lymphovascular invasion, and urothelial carcinoma) were found to have significantly more often higher BTG2 levels when compared with patients with age \<65 years, tumour stages 1 and 2, low grading (grades 1 and 2), and SCC ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

As shown in [Figure 6A](#fig6){ref-type="fig"}, Kaplan--Meier cancer-specific survival curves of the whole cohort of patients (all histologies) revealed a significantly worse prognosis in patients with high BTG2 levels compared with low and moderate BTG2 levels (*P*=0.02). In subgroup analyses of patients with urothelial carcinoma or SCC of the bladder, high levels of BTG2 showed a strong tendency towards being an independent predictor of poor cancer-specific survival (*P*=0.05 and *P*=0.12, respectively; [Figure 6B and C](#fig6){ref-type="fig"}).

On univariate survival analyses, the risk of death from bladder cancer for patients showing high BTG2 levels in the tumour was significantly enhanced above that for bladder cancer patients who exhibited low BTG2 levels ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}, HR 2.01, *P*=0.007). Apart from BTG2, the following clinical and histopathological features showed a statistically significant impact on cancer-specific survival in bladder cancer patients in univariate analyses: tumour stage, grading, histopathological subtype, lymph node involvement, metastatic disease, age, and lymphovascular invasion ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). In subgroup analyses of urothelial carcinoma, the risk of death for patients with high BTG2 levels in the tumour was also clearly enhanced above that for patients who have low BTG2 levels ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}, HR=2.4, *P*=0.02). In contrast, no significant association between BTG2 and the risk of death was obtained in subgroup analyses of SCC (HR=3.14, *P*=0.14).

Next, we investigated whether BTG2 may also independently correlate with cancer-specific survival in urinary bladder cancer. Multivariate Cox regression analyses on bladder cancer outcome included tumour stage, lymph node involvement, metastatic disease, grading, lymphovascular invasion, concomitant carcinoma *in situ*, age, sex, histopathological subtype, and BTG2 expression. These analyses revealed that high BTG2 expression displays a strong tendency to be an independent prognostic marker of cancer-specific survival ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}, HR=2.31, *P*=0.09). Apart from BTG2 expression, histopathological subtype, lymph node involvement, and grading were selected as important prognostic indicators ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Furthermore, in a multivariate analysis excluding BTG2, the same variables without lymph node involvement were selected as prognostic indicators ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

In a prognostic model based on the multivariate fractional polynomial (MFP) method, BTG2 as continuous variable and the same categorical variables as in the multivariate Cox regression model were included in the analysis. The MFP algorithm works iteratively, selecting out covariates with a *P*-value \>0.15. At the final cycle, the MFP algorithm selected the following predictors as important prognostic indicators on cancer-specific survival: BTG2, histopathological subtype, tumour stage, lymph node involvement, and grading ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}).

Finally, for further evaluation of the predictive value of BTG2 expression, the concordance probability of the Cox regression models including or excluding BTG2 was calculated. The concordance probability of the Cox regression models including the BTG2 status was 0.743 with a standard error of 0.027, compared with 0.737 with a standard error of 0.028 in models excluding the BTG2 status but retaining all other variables.

Discussion
==========

The present study is the first investigation of the status and function of the putative tumour-suppressor gene *BTG2* in cancers of the urinary bladder. We obtained two major unexpected results. First, we observed that *BTG2* suppression resulted in a strongly reduced cell motility. These findings indicate that *BTG2* expression in bladder cancer cells contributes to their migration ability. Second, and in contrast to reports from other cancer entities, we observed that elevated BTG2 expression levels in bladder cancers were linked to a strongly decreased cancer-specific survival.

Our conclusion that *BTG2* suppression leads to a reduced migration capacity of bladder cancer cells is based on different *BTG2*-targeting siRNAs that yielded confirmatory results and on two independent cell migration assays: the wound healing (scratch) and the Boyden chamber assay. These two tests methodologically differ in that the Boyden chamber assay requires cells to release intercellular contacts and therefore allows cell motility analyses that are largely independent of cell--cell interactions ([@bib6]). Both assays yielded consistent results, showing a profound reduction of bladder cancer cell migration upon *BTG2* suppression. The observation that *BTG2* suppression did not markedly affect cell viability or cell proliferation of bladder cancer cells, as assessed by BrdU and cell cycle analyses, provides strong evidence that the results of the migration assays reflect real cell migration and not altered cell proliferation.

The positive correlation between *BTG2* expression and the migration capacity of bladder cancer cells contrasts the situation in breast cancer cells where these parameters exhibited an inverse correlation ([@bib36]). This indicates that BTG2 can exert differential effects on cellular migration, depending on the cellular context. The issue of cancer cell migration is of particular interest for the genesis of urothelial bladder cancers that often present themselves as multifocal tumours in the urothelial tract of a single patient. Accumulating molecular evidence suggests that these lesions are descendants of the intraepithelial (or intraluminal) spread of a single transformed cell ([@bib18]; [@bib38]).

Interesting differences were also observed for the *in vivo* BTG2 expression pattern between urothelial and SCC of the bladder. Less than 10% of the urothelial carcinomas exhibited low or undetectable BTG2 levels -- in contrast to ∼80% of SCCs. This observation is likely to reflect differences in the molecular pathogenesis of these two histological bladder cancer variants ([@bib38]; [@bib32]). In addition, we observed survival differences by the two histological subtypes: although the grading of urothelial carcinoma was significantly worse than in SCC ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}), it was more likely to die because of a SCC than of an urothelial carcinoma of the bladder ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}, HR 2.48).

Previous studies showed that higher BTG2 expression levels in tumours were linked to a better clinical prognosis for breast, renal, and prostate cancer patients ([@bib35]; [@bib30]; [@bib21]). In contrast, we observed a strongly increased risk of death from urinary bladder cancer for patients exhibiting high BTG2 levels in the tumour tissue when compared with patients with low BTG2 levels ([Figure 6A](#fig6){ref-type="fig"}). This increased risk was statistically significant in univariate Cox regression analyses ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}, *P*=0.007) and remained as a strong tendency in multivariate Cox regression analyses ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}, *P*=0.09). In multivariate fractional polynomials, ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}, *P*=0.014), an alternative approach using BTG2 as a continuous variable, BTG2 was also found to be an independent prognostic factor. In subgroup analyses of urothelial carcinoma, univariate Cox regression analyses again demonstrated increased levels of BTG2 as a significant risk factor for cancer-specific death ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}, *P*=0.02). In contrast, in subgroup analyses of SCC, this significance was lost ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}, *P*=0.14), possibly because of the small number of patients (*n*=46). The concordance probability estimated for the multivariate Cox regression model incorporating BTG2 was 0.743 with a standard error of 0.027. The estimation of the concordance probability after excluding BTG2 was in a very similar range (0.737, standard error of 0.028). Taken together, and in marked contrast to the results for other tumour entities, these findings provide evidence that higher levels of BTG2 expression within urinary bladder cancers are associated with a strongly decreased cancer-specific survival of affected patients. Despite this evidence, we did not see an increase in the concordance probability including or excluding BTG2 expression in our predictive model. To increase the predictive accuracy, BTG2 expression should be included into molecular multimarker panels as these are more likely to accurately predict outcomes in invasive bladder cancer than any single marker ([@bib14]).

In conclusion, our study shows that inhibition of endogenous *BTG2* expression substantially reduced the motility of bladder cancer cells. This finding indicates that the endogenous *BTG2* expression in bladder cancer cells contributes to their migratory potential and thereby may promote tumourigenesis. Furthermore, we found that increased intratumoural BTG2 levels are linked to a less favourable clinical outcome for bladder cancer patients. These results are in marked contrast to previous investigations in other cancer entities where *BTG2* is thought to act antioncogenic (e.g., antiproliferative, antimigratory) and where increased *BTG2* expression is linked to a more favourable clinical outcome. Our findings thus indicate that the endogenous activities of *BTG2* are cell type dependent. They question the conception that BTG2 generally acts as a tumour suppressor and that BTG2 expression typically represents a favourable clinical marker in cancer patients.
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![**The expression of *BTG2* in bladder cancer cells and its modulation by RNA interference.** (**A**) Quantitative real-time reverse transcription--PCR (qRT--PCR) analyses of *BTG2* mRNA expression. Data are represented as fold differences in gene expression, normalised to GAPDH expression. White columns, semiconfluent conditions; grey columns, confluent conditions. Standard deviations from at least two independent experiments are indicated. \*Statistically significant difference (*P*\<0.05). (**B**) The qRT--PCR analyses of *BTG2* mRNA levels following treatment with 0.5 *μ*g ml^−1^ doxorubicin for 24 h. The mRNA levels of *BTG2* in doxorubicin-treated cells are indicated relative to those in corresponding solvent-treated control cells (arbitrarily set at 1.0). Standard deviations are indicated. (**C**) The qRT--PCR analyses of *BTG2* mRNA levels following treatment with 1 *μ*ℳ retinoic acid (r.a.) for 24 h. The mRNA levels of *BTG2* in r.a.-treated cells are indicated relative to those in corresponding solvent-treated control cells (arbitrarily set at 1.0). Standard deviations are indicated. (**D**) The qRT--PCR analyses of *BTG2* mRNA levels following siRNA treatment of bladder cancer cells. The siBTG2-3, siBTG2-5, and siBTG2-9 target three different regions within the *BTG2* mRNA; siBTG2-5/9 corresponds to a pool of equal amounts of siBTG2-5 and siBTG2-9; siNeg and sicontr-1 served as negative control siRNAs. For each cell line, *BTG2* mRNA levels are indicated relative to those in corresponding siNeg-treated control cells (arbitrarily set at 1.0 for each cell line). Standard deviations are indicated. (**E**) Immunoblot analyses of BTG2 protein levels upon siRNA treatment of RT112 bladder cancer cells. Mock, cells undergoing the transfection procedure in the absence of siRNAs; siEGFP and sicontr-1 served as negative control siRNAs; siBTG2-3 and siBTG2-5 target two different regions in the *BTG2* mRNA; siBTG2-3/5 corresponds to a pool of equal amounts of siBTG2-3 and siBTG2-5. Tubulin, loading control.](bjc2012573f1){#fig1}

![**Analysis of bladder cancer cell proliferation upon RNAi-mediated inhibition of *BTG2* expression.** (**A**) Measurement of BrdU incorporation in RT112, SCaBER, 5637, and T24 bladder cancer cells. For each cell line, the percentage of BrdU incorporation upon siRNA application is indicated relative to that in corresponding siNeg-treated control cells (set at 100% for each cell line). The siNeg and sicontr-1 served as control siRNAs; siBTG2-5/9 corresponds to a pool of equal amounts of siBTG2-5 and siBTG2-9. Standard deviations are indicated. (**B**) Fluorescence-activated cell sorting (FACS) analyses investigating the cell cycle distribution of bladder cancer cells following inhibition of *BTG2* expression. Percentages of cells in the G1, S, or G2/M phases upon treatment with control siRNAs (siNeg, sicontr-1) or with pooled siRNAs blocking *BTG2* expression (siBTG2-5/9) are indicated.](bjc2012573f2){#fig2}

![**'Wound healing (scratch)\' assays analysing the effects of *BTG2* suppression on the migration of bladder cancer cells.** (**A**) The 5637 cells were transfected with the indicated siRNAs and subjected to *in vitro* wound healing assays. Images were captured by light microscopy. Dotted lines define the areas lacking cells ('scratches\'), at time point 0. Cells that had migrated into the scratch areas were counted after 8--10 h. The siNeg and sicontr-1 served as control siRNAs; siBTG2-5 and siBTG2-9 are two unrelated siRNAs blocking *BTG2* expression. (**B**) Quantification of the effect of *BTG2* suppression on the migration of RT122, SCaBER, 5637, and T24 cells in wound healing assays. For each cell line, percentages of migrated cells were determined relative to cells treated with control siRNA siNeg (set at 100%). Standard deviations are indicated.](bjc2012573f3){#fig3}

!['Boyden chamber\' assays analysing the effects of *BTG2* suppression on the migration of bladder cancer cells. Cells were sown on the upper side of a porous membrane separating the two compartments of the migration chamber. Cells that had migrated through the pores to the lower side of the membrane were fixed and stained with crystal violet. Individual bladder cancer cell lines are indicated. n.d., not done. siNeg, sicontr-1 served as negative control siRNAs; siBTG2-5 and siBTG2-9 are two unrelated siRNAs blocking BTG2 expression; siBTG2-5/9 corresponds to an equimolar mixture of siBTG2-5 and siBTG2-9.](bjc2012573f4){#fig4}

![**The expression of BTG2 in urinary bladder cancer. Overviews (left panels) and higher-resolution presentations (right panels) of the boxed areas.** (**A**) Urothelial carcinoma of the urinary bladder, showing high cytoplasmic/membranous BTG2 expression (indicated by arrows). (**B**) Urothelial carcinoma of the urinary bladder, showing moderate cytoplasmic/membranous BTG2 expression (indicated by arrows). (**C**) Urothelial carcinoma of the urinary bladder, showing low cytoplasmic/membranous BTG2 expression. (**D**) Squamous cell carcinoma of the urinary bladder, showing no BTG2 expression. Scale bars, 5 *μ*m.](bjc2012573f5){#fig5}

![**Kaplan--Meier survival curves of cancer-specific survival.** (**A**) Cancer-specific survival rates of urinary bladder cancer patients (all histologies). (**B**) Cancer-specific survival rates in urothelial carcinoma of the bladder. (**C**) Cancer-specific survival rates in squamous cell carcinoma of the bladder.](bjc2012573f6){#fig6}
